Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that the United States Food and Drug Administration (FDA) informed the company yesterday that a clinical hold has been placed on patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer. Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares after opening at $7.97 moved to $8.27 on last trade day and at the end of the day closed at $8.12. Company price to sales ratio in past twelve months was calculated as 18.38 and price to cash ratio as 14.08. Halozyme Therapeutics, Inc. (NASDAQ:HALO) showed a negative weekly performance of -33.11%.
PharmAthene, Inc. (AMEX:PIP) announced that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax anthrax vaccine contract through a partial termination for convenience. PharmAthene, Inc. (NYSEMKT:PIP) shares fell -2.52% in last trading session and ended the day on $1.55. PIP return on equity ratio is recorded as -111.00% and its return on assets is -55.00%. PharmAthene, Inc. (NYSEMKT:PIP) yearly performance is -4.91%.
Zacks assumed coverage on shares of Ignyta (NASDAQ:RXDX). The firm issued a hold rating on the stock. Ignyta Inc (NASDAQ:RXDX) shares moved down -1.65% in last trading session and was closed at $6.57 while trading in range of $6.45 – $6.78 – Ignyta Inc (NASDAQ:RXDX) year to date (YTD) performance is -67.15%.
Ventrus Biosciences Inc (NASDAQ:VTUS) announced that the U.S. Food and Drug Administration or FDA has scheduled a Type B pre-NDA meeting on Thursday, June 19, 2014 at which the company will seek guidance on its planned new drug application or NDA for Dolizem (diltiazem hydrochloride cream) in anal fissures. Ventrus Biosciences Inc (NASDAQ:VTUS) weekly performance is -1.63%. On last trading day company shares ended up $1.21. Ventrus Biosciences Inc (NASDAQ:VTUS) distance from 50-day simple moving average (SMA50) is -39.55%. Analysts mean target price for the company is $2.50.
Leave a Reply